A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease

Completed · Phase 4 · Has a placebo group

Conditions studied: Fabry Disease

In brief

People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme (agalsidase beta) is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid ("globotriaosylceramide" or "GL-3") levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study will test the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease.

Key facts

Study ID: NCT00074984
Run by: Genzyme, a Sanofi Company
People needed: 82
Starts: 2001-02-01
Expected to finish: 2004-01-01
Last updated by the study team: 2013-12-27

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must provide written informed consent
Patients must be at least 16 years old
Patients must have a current diagnosis of Fabry disease and have a clinical presentation consistent of Fabry disease (decreased sweating, Fabry pain, angiokeratoma, etc.)
Patients may not have received enzyme replacement therapy as a treatment for Fabry disease
Patients must have a documented plasma a-galactosidase A (aGAL) activity of < 1.5 nmol/hr/mL or a documented leukocyte aGAL activity of < 4 nmol/hr/mg
Patients must have one or more of the following: a serum creatinine measurement of 1.2 to 3 mg/dL (106.1 to 265 umol/L) OR estimated creatinine clearance < 80 mL/min only if the patient's serum creatinine measurement is < 1.2 mg/dL
Female patients of childbearing potential must have a negative pregnancy test prior to each dosing and all female patients must use a medically accepted form of contraception

You may not qualify if…

Patient has undergone or is currently scheduled for kidney transplantation or is currently on dialysis
Patient has acute renal failure
Patient has participated in a study employing an investigational drug within 30 days of study entry
Patient has diabetes mellitus or presence of confounding renal disease
Patient has a history of transient ischemic attack (TIA) or ischemic stroke within 3 months of study entry documented by mild-to-moderate neurological deficit
Patient has critical coronary disease
Patient has congestive heart failure
Patient has severe residual neurological deficit that will confound the detection of new events as determined by an attending neurologist and/or Principal Investigator
Patient is unwilling to comply with the requirements of the protocol or the patient has a medical condition, serious intercurrent illness, or extenuating circumstances that would significantly decrease study compliance, including prescribed follow-up

Where it is running

University of Alabama at Birmingham — Birmingham, Alabama, United States
Cedars-Sinai Medical Center — Los Angeles, California, United States
University of San Francisco — San Francisco, California, United States
University of Connecticut Health Partners — Farmington, Connecticut, United States
Oncology Hematology Association — Coral Springs, Florida, United States
Emory University School of Medicine — Atlanta, Georgia, United States
Children's Memorial Hospital — Chicago, Illinois, United States
University of Kansas Medical Center — Kansas City, Kansas, United States
Massachusetts General Hospital — Boston, Massachusetts, United States
Gene Therapy Center - Dept. of Pediatrics and Institute of Human Genetics — Minneapolis, Minnesota, United States
Children's Hospital — Buffalo, New York, United States
Mount Sinai School of Medicine — New York, New York, United States
University of Rochester School of Medicine — Rochester, New York, United States
Duke University Medical Center — Durham, North Carolina, United States
Children's Hospital Medical Center — Cincinnati, Ohio, United States
Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
University of Pittsburgh — Pittsburgh, Pennsylvania, United States
Baylor College of Medicine — Houston, Texas, United States
University of Washington School of Medicine — Seattle, Washington, United States
Queen Elizabeth II Health Center — Halifax, Nova Scotia, Canada
North York General Hospital — Toronto, Ontario, Canada
Hopital du Sacre-Coeur de Montreal — Montreal, Quebec, Canada
University Hospital — Prague, Czechia
Sopron Megyei Jogu Varos Erzsebet Korhaz — Sopron, Hungary
Klinika Chorob Metabolicznych Instytut — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.